Inhibikase Therapeutics, Inc. SEC filings IKT
Inhibikase Therapeutics, Inc. has 368 filings in SEC EDGAR's recent list, going back to Aug 31, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 26, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2026 | Jun 26, 2026 |
| DEFA14A | Additional proxy material | Jun 12, 2025 | — |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| DEF 14A | Proxy statement | May 12, 2025 | Jun 27, 2025 |
| PRE 14A | Preliminary proxy statement | May 2, 2025 | Jun 27, 2025 |
| DEF 14A | Proxy statement | Nov 18, 2024 | Jan 3, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 8, 2024 | Jan 3, 2025 |
| DEFA14A | Additional proxy material | Jun 21, 2024 | — |
| DEF 14A | Proxy statement | Jun 20, 2024 | Aug 5, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 10, 2024 | Aug 5, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2024 | Jun 7, 2024 |
| DEFA14A | Additional proxy material | May 12, 2023 | — |
| DEF 14A | Proxy statement | May 5, 2023 | Jun 23, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2023 | Jun 23, 2023 |
| DEFA14A | Additional proxy material | May 3, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 24, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2022 | Jun 24, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 25, 2021 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750149
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.